Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy

Show full item record



Permalink

http://hdl.handle.net/10138/309709

Citation

Ylösmäki , L , Polini , B , Carpi , S , Martins , B , Smertina , E , Feola , S , Fusciello , M , Peltonen , K , Nieri , P , Ylösmäki , E & Cerullo , V 2019 , ' Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy ' , PLoS One , vol. 14 , no. 10 , pp. e0224072 . https://doi.org/10.1371/journal.pone.0224072

Title: Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy
Author: Ylösmäki, Leena; Polini, Beatrice; Carpi, Sara; Martins, Beatriz; Smertina, Elena; Feola, Sara; Fusciello, Manlio; Peltonen, Karita; Nieri, Paola; Ylösmäki, Erkko; Cerullo, Vincenzo
Contributor: University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, ImmunoViroTherapy Lab
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, Division of Pharmaceutical Biosciences
Date: 2019-10-23
Language: eng
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/309709
Abstract: Messenger RNA (mRNA) and microRNA (miRNA)-based therapeutics have become attractive alternatives to DNA-based therapeutics due to recent advances in manufacture, scalability and cost. Also, RNA-based therapeutics are considered safe since there are no risk of inducing genomic changes as well as the potential adverse effects would be only temporary due to the transient nature of RNA-based therapeutics. However, efficient in vivo delivery of RNA-based therapeutics remains a challenge. We have developed a delivery platform for RNA-based therapeutics by exploiting the physicochemical properties of enveloped viruses. By physically attaching cationic liposome/RNA complexes onto the viral envelope of vaccinia virus, we were able to deliver mRNA, self-replicating RNA as well as miRNA inside target cells. Also, we showed that this platform, called viRNA platform, can efficiently deliver functional miRNA mimics into B16.OVA tumour in vivo.
Subject: 317 Pharmacy
318 Medical biotechnology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
journal.pone.0224072.pdf 2.244Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record